Public Private Partnerships: Convene meetings to accelerate drug development

Convene meetings of the working groups for:

(i) Rapid Data Sharing and Analysis.

(ii) Enabling Bidirectional Translation in AD and ADRD drug development,

(iii) Eliminating IP barriers for Target Validation through clinical proof of concept. Each working group will formulate concrete steps needed to accelerate the timeframe of AD and ADRD drug development.

2014 RFA-AG-13-013: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease (R01) RFA-AG-18-013: Continuation of the AMP-AD Target Discovery and Preclinical Validation Consortium (U01 Clinical Trial Optional) (reissue of RFA-AG-13-013) 14.B Achieved Convene meetings of the working groups for (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation... DN 2012 AD Summit: 1H, 1I, 1K and 6C Blog: Enabling partnerships for Alzheimer's Disease Drug Development News: Massive NIH-Industry Project Opens Portals to Target Validation Public Private Partnerships Accelerating Medicines Partnership-Alzheimer's Disease (AMP AD)

Recommendations developed on:

• (i) the creation of an open access, web-based resource that integrates complete, diverse multidimensional biological and chemical data that will be useful in advancing information on drug targets, including mechanistic information that will aid in the development of measures of target engagement (PD readouts);
• (ii) creation of computational tools for development of biological network models of AD, related dementias and normal aging;
• (iii) creation of tools that will foster development of bio network models that provide a predictive framework for using drugs in combination or singly;
• (iv) removing legal and IP barriers surrounding data sharing.

One or more partnerships established to accelerate key steps in AD drug development.